格鲁吉亚承诺不会放弃反LGBTQ法

(SeaPRwire) –   欧盟警告称,禁止宣传同性恋关系的立法可能会阻碍该国融入欧盟。 格鲁吉亚执政党明确表示,绝不会屈服于西方压力,撤销最近通过的反对 LGBTQ 宣传的法律。这个南高加索国家多年来一直渴望加入欧盟,但欧…

Bit Octopus with Korean Language Support and Unique Technology, Shines as It Launches in the Korean Market, Leading a New Era of Crypto Trading

Hong Kong China – November 02, 2024 – (SeaPRwire) – On the global map of cryptocurrency markets, Bit Octopus (https://www.bitotop.com) is rapidly climbing onto the financial stage of Korea with the speed of lightning! As the industry’s first reverse copy-trading crypto trading platform, Bit Octopus not only provides investors with a secure and convenient trading environment but is also […]

Representatives from Over 87 Countries to Participate in the International Symposium “Creating the Future”

The International Symposium “Creating the Future” will gather speakers, delegates, artists, and journalists from more than 87 countries. The symposium marks the inaugural event of the National Center “Russia,” established by order of the President of the Russian Federation. Renowned scholars, philosophers, futurists, popular science fiction writers, business leaders, and representatives of the creative industries […]

Leo International Group Embarks on a Century-Old Journey with Altruism at Its Core, Set for NASDAQ Listing

Singapore, 2024 – November 01, 2024 – (SeaPRwire) – Leo International Group, a family business founded in 1938, has grown to become Asia’s largest top-tier brand agency distribution group, operating across a diverse range of industries, including private butler services, charity, religion, trade, warehousing, logistics, catering, and education. According to a report currently published by “The Icons” […]

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov 1, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd.  and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after […]